4DMedical Ltd (ASX: 4DX) shares have jumped another 2.3% higher in Thursday afternoon trade. At the time of writing, the shares are changing hands at $6.37 a piece.
The uptick means the shares have now rocketed 55% over the past week. They're now up a huge 71% over the past month and are 40% higher over the year to date.
Most impressively, 4DX shares are 1,890% higher than this time 12 months ago, driven by regulatory approvals and a portfolio of signed contracts with hospitals and medical providers.
The ASX healthcare technology company develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung and respiratory diseases ranging from asthma to lung cancer.
The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.
4DMedical has already signed contracts with hospitals and medical providers, primarily across the US. Stanford University, the University of Miami, Cleveland Clinic, and UC San Diego Health have all rolled out the technology at their centres.
So, why are 4DX shares in the spotlight this week?
4DX announced yesterday that its CT:VQ has now been deployed at the Mayo Clinic in the US for ventilation and perfusion analysis.
The clinic is widely-regarded as one of the world's leading hospitals. This makes it a landmark moment for 4DX and its shares.
The news comes amid the company's rapid repositioning from a research and development business trialling new technology, to a globally commercial business. And this has happened within a very short period of time.
Investors are clearly jumping on board and it is sending the share price flying.
What's next for 4DX in 2026?
Development and rapid adoption of the company's technology also mean 4DMedical has smashed its milestone goals this year.
Approvals have been secured in Canada and New Zealand, and now the company is turning its attention to Europe and Australia.
What's the outlook for 4DX shares?
The latest share price surge even took analysts by surprise. Despite the majority of brokers holding a strong buy ratings, the target prices all now imply a significant downside for 4DX shares from here. We may see analysts confirm or update their expectations for the shares in coming days.
What's clear though, is that the share price rally demonstrates high expectations for the outlook of the company's growth. I think we'll see plenty more from 4DX shares this year.
The post Why is everyone talking about 4DX shares this week? appeared first on The Motley Fool Australia.
Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026